Femasys (FEMY) Stock
Small medical device developer for women's reproductive health. Here's the price, business snapshot, and what's worth knowing about Femasys in October 2026.
Femasys Inc (FEMY) is a micro-cap medical device company focused on women’s reproductive health. The business develops minimally invasive diagnostic and procedural tools intended to address fertility and gynaecological needs. Investors should note the company’s small market capitalisation (about $27.5 million), which can mean limited liquidity, higher volatility and greater sensitivity to clinical, regulatory and financing news. Potential upside could come from successful product adoption, regulatory clearances or commercial partnerships, but these outcomes are uncertain and may take time. Financial performance for very small medical-device firms can be uneven and dependent on discrete contracts, trial results and reimbursement dynamics. This summary is educational and not investment advice; values can rise and fall and past performance is not a guide. Before deciding on FEMY, consider your risk tolerance, check the company’s filings for up-to-date results, and consult a regulated financial adviser for personalised guidance.
Femasys (FEMY) Stock Forecast
Analyst price target, next 12 months
$12.00
+485.4% vs today's $2.05
Price range over the last 12 months
Close to its 12-month low
Analysts covering Femasys have a consensus 12-month target of $12.00, above the current price of $2.05.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying FEMASYS stock with a target price of $12, indicating growth potential.
Financial Health
Femasys Inc shows promising revenue and cash flow, with a strong gross margin indicating efficient operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early-stage potential
Small market cap means more room for growth if products gain traction, though share prices can swing sharply and outcomes are uncertain.
Regulatory impact
Clinical data and approvals can materially affect prospects; regulatory milestones are catalysts but also carry execution risk.
Market and adoption
Addressing women’s reproductive health can tap large, underserved markets, but commercial uptake and reimbursement may take time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.